454 related articles for article (PubMed ID: 33235142)
1. Management of an Immunocompromised Pediatric Patient With Multiple Hospitalizations for Symptomatic COVID-19.
DeVine MN; Maxwell S; Haynes AS; MacBrayne CE; Boguniewicz J
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e293-e295. PubMed ID: 33235142
[TBL] [Abstract][Full Text] [Related]
2. A 10-Year-old Girl With Late Acute Lymphoblastic Leukemia Recurrence Diagnosed With COVID-19 and Treated With Remdesivir.
Gadzińska J; Kuchar E; Matysiak M; Wanke-Rytt M; Kloc M; Kubiak JZ
J Pediatr Hematol Oncol; 2022 Mar; 44(2):e537-e538. PubMed ID: 33885040
[TBL] [Abstract][Full Text] [Related]
3. Neonates With SARS-CoV-2 Infection and Pulmonary Disease Safely Treated With Remdesivir.
Saikia B; Tang J; Robinson S; Nichani S; Lawman KB; Katre M; Bandi S
Pediatr Infect Dis J; 2021 May; 40(5):e194-e196. PubMed ID: 33847299
[TBL] [Abstract][Full Text] [Related]
4. Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.
Camprubí D; Gaya A; Marcos MA; Martí-Soler H; Soriano A; Mosquera MDM; Oliver A; Santos M; Muñoz J; García-Vidal C
Int J Infect Dis; 2021 Mar; 104():379-381. PubMed ID: 33359065
[TBL] [Abstract][Full Text] [Related]
5. Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy.
Helleberg M; Niemann CU; Moestrup KS; Kirk O; Lebech AM; Lane C; Lundgren J
J Infect Dis; 2020 Sep; 222(7):1103-1107. PubMed ID: 32702095
[TBL] [Abstract][Full Text] [Related]
6. Immune responses and therapeutic challenges in paediatric patients with new-onset acute myeloid leukaemia and concomitant COVID-19.
Patel PA; Lapp SA; Grubbs G; Edara VV; Rostad CA; Stokes CL; Pauly MG; Anderson EJ; Piantadosi A; Suthar MS; Khurana S; Sabnis HS
Br J Haematol; 2021 Aug; 194(3):549-553. PubMed ID: 34096051
[No Abstract] [Full Text] [Related]
7. Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
Wu TY; Chen PY; Wang JT; Liu WD; Chen YC; Chang SC
J Antimicrob Chemother; 2024 May; 79(5):1196-1200. PubMed ID: 38538154
[No Abstract] [Full Text] [Related]
8. Compassionate use of remdesivir in children with COVID-19.
Méndez-Echevarría A; Pérez-Martínez A; Gonzalez Del Valle L; Ara MF; Melendo S; Ruiz de Valbuena M; Vazquez-Martinez JL; Morales-Martínez A; Remesal A; Sándor-Bajusz KA; Cabañas F; Calvo C
Eur J Pediatr; 2021 Apr; 180(4):1317-1322. PubMed ID: 33200304
[TBL] [Abstract][Full Text] [Related]
9. Management and Outcome of Coronavirus Disease 2019 (COVID-19) in Pediatric Cancer Patients: A Single Centre Experience from a Developing Country.
Hammad M; Shalaby L; Sidhom I; Sherief N; Abdo I; Soliman S; Madeny Y; Hassan R; Elmeniawy S; Khamis N; Zaki I; Mansour T; El-Ansary MG; Al-Halfawy A; Abouelnaga S; Elhaddad A
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e853-e864. PubMed ID: 34420893
[TBL] [Abstract][Full Text] [Related]
10. Remdesivir (Veklury) for the Treatment of COVID-19 in Hospitalized Patients.
Odeti S; Yellepeddi VK
Am Fam Physician; 2021 Sep; 104(3):311-312. PubMed ID: 34523893
[No Abstract] [Full Text] [Related]
11. Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.
Negru PA; Radu AF; Vesa CM; Behl T; Abdel-Daim MM; Nechifor AC; Endres L; Stoicescu M; Pasca B; Tit DM; Bungau SG
Biomed Pharmacother; 2022 Mar; 147():112700. PubMed ID: 35131656
[TBL] [Abstract][Full Text] [Related]
12. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
Khazir J; Maqbool T; Mir BA
Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study.
Węcławek-Tompol J; Zakrzewska Z; Gryniewicz-Kwiatkowska O; Pierlejewski F; Bień E; Zaucha-Prażmo A; Zając-Spychała O; Szmydki-Baran A; Mizia-Malarz A; Bal W; Sawicka-Żukowska M; Kruk A; Ociepa T; Raciborska A; Książek A; Szczepański T; Peregud-Pogorzelski J; Krawczuk-Rybak M; Chaber R; Matysiak M; Wachowiak J; Irga-Jaworska N; Młynarski W; Dembowska-Bagińska B; Balwierz W; Matkowska-Kocjan A; Kazanowska B; Styczyński J; Ussowicz M
J Hematol Oncol; 2021 Oct; 14(1):163. PubMed ID: 34635137
[TBL] [Abstract][Full Text] [Related]
14. Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma.
Maruki T; Nomoto H; Iwamoto N; Yamamoto K; Kurokawa M; Iwatsuki-Horimoto K; Yamayoshi S; Suzuki Y; Kawaoka Y; Ohmagari N
J Infect Chemother; 2024 Aug; 30(8):793-795. PubMed ID: 38242284
[TBL] [Abstract][Full Text] [Related]
15. Use of Remdesivir in Myasthenia gravis and COVID-19.
Peters BJ; Rabinstein AA; DuBrock HM
Pharmacotherapy; 2021 Jun; 41(6):546-550. PubMed ID: 33835512
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.
Humeniuk R; Mathias A; Kirby BJ; Lutz JD; Cao H; Osinusi A; Babusis D; Porter D; Wei X; Ling J; Reddy YS; German P
Clin Pharmacokinet; 2021 May; 60(5):569-583. PubMed ID: 33782830
[TBL] [Abstract][Full Text] [Related]
17. Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients.
Weinbergerova B; Mayer J; Kabut T; Hrabovsky S; Prochazkova J; Kral Z; Herout V; Pacasova R; Zdrazilova-Dubska L; Husa P; Bednar P; Ruzek D; Lengerova M
Hematol Oncol; 2021 Dec; 39(5):715-720. PubMed ID: 34396566
[No Abstract] [Full Text] [Related]
18. Dynamic diversity of SARS-CoV-2 genetic mutations in a lung transplantation patient with persistent COVID-19.
Igari H; Sakao S; Ishige T; Saito K; Murata S; Yahaba M; Taniguchi T; Suganami A; Matsushita K; Tamura Y; Suzuki T; Ido E
Nat Commun; 2024 Apr; 15(1):3604. PubMed ID: 38684722
[TBL] [Abstract][Full Text] [Related]
19. No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials.
Hedskog C; Spinner CD; Protzer U; Hoffmann D; Ko C; Gottlieb RL; Askar M; Roestenberg M; de Vries JJC; Carbo EC; Martin R; Li J; Han D; Rodriguez L; Parvangada A; Perry JK; Ferrer R; Antón A; Andrés C; Casares V; Günthard HF; Huber M; McComsey GA; Sadri N; Aberg JA; van Bakel H; Porter DP
Viruses; 2024 Mar; 16(4):. PubMed ID: 38675889
[TBL] [Abstract][Full Text] [Related]
20. Update Alert 2: Remdesivir for Adults With COVID-19.
Kaka AS; MacDonald R; Linskens EJ; Wilt TJ
Ann Intern Med; 2021 Dec; 174(12):W114-W115. PubMed ID: 34606312
[No Abstract] [Full Text] [Related]
[Next] [New Search]
